Drug Trial Radar · NCT04368585
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Sep 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jul 1, 2020
Primary completion
Aug 8, 2020
Study completion Aug 21, 2020
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.
Conditions
- Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)Drug
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)Drug
20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
OmeprazoleDrug
40 mg (1 x 40 mg capsule) omeprazole administered QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Area under the curve extrapolated to infinity (AUC0-∞).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Percent of AUC0-inf extrapolated (AUC%extrap)Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Maximum plasma concentration (Cmax).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Time to the maximum plasma concentration (Tmax).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Terminal elimination half-life (t½).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Apparent total body clearance (CL/F)Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
- Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Facility
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.